GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » Price-to-Owner-Earnings

Steminent Biotherapeutics (ROCO:7729) Price-to-Owner-Earnings : (As of May. 30, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics Price-to-Owner-Earnings?

As of today (2025-05-30), Steminent Biotherapeutics's share price is NT$21.65. Steminent Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Steminent Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ROCO:7729's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.765
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-30), Steminent Biotherapeutics's share price is NT$21.65. Steminent Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-2.84. Therefore, Steminent Biotherapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-30), Steminent Biotherapeutics's share price is NT$21.65. Steminent Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was NT$-2.84. Therefore, Steminent Biotherapeutics's PE Ratio without NRI for today is At Loss.


Steminent Biotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Steminent Biotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics Price-to-Owner-Earnings Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
- - - - -

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of Steminent Biotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Steminent Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's Price-to-Owner-Earnings falls into.


;
;

Steminent Biotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Steminent Biotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=21.65/-3.31
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steminent Biotherapeutics  (ROCO:7729) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Steminent Biotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Steminent Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines